ABSTRACT
Objetivo: descrever o significado do uso da prótese peniana de silicone para dilatação vaginal no seguimento da braquiterapia em mulheres com câncer ginecológico. Método: pesquisa narrativa, realizada no Centro de Pesquisas Oncológicas, Brasil, com 34 mulheres, após braquiterapia pélvica, em seguimento no serviço de fisioterapia. Coleta de dados por entrevistas semiestruturadas, incluindo dados sociodemográficos, clínicos e o significado do uso da prótese peniana na dilatação vaginal, submetidas à análise de conteúdo e discutidas à luz do estudo From 'sex toy' to intrusive imposition. Resultados: o significado perpassa o exercício de dilatação vaginal; as dificuldades relacionadas às condições vaginais, doença, tratamento, dor, sexo, constrangimentos, preconceitos, falhas na educação em saúde; as motivações relacionam-se à busca por qualidade de vida, apoio dos companheiros e profissionais. Conclusão: a abordagem de possíveis barreiras emocionais, psicológicas, sociais e físicas deve ser planejada e executada para prevenção da estenose vaginal e melhor acolhimento.
Objective: to describe the meaning of the use of silicone penile prosthesis for vaginal dilation in the follow-up of brachytherapy in women with gynecological cancer. Method: narrative research conducted at the Centro de Pesquisas Oncológicas, Brazil, with 34 women after pelvic brachytherapy, under follow-up at the physical therapy service. Data collection through semi-structured interviews, including sociodemographic and clinical data and the significance of the use of penile prosthesis in vaginal dilation, submitted to content analysis and discussed in the light of the study From 'sex toy' to intrusive imposition. Results: the meaning permeates the vaginal dilation exercise; difficulties related to vaginal conditions, disease, treatment, pain, sex, constraints, prejudices, failures in health education; motivations are related to the search for quality of life, support of partners and professionals. Conclusion: the approach of possible emotional, psychological, social and physical barriers should be planned and executed for prevention of vaginal stenosis and better reception.
Objetivo: describir el significado del uso de una prótesis peneana de silicona para la dilatación vaginal posterior a la braquiterapia en mujeres con cáncer ginecológico. Método: investigación narrativa, realizada en el Centro de Pesquisas Oncológicas, Brasil, con 34 mujeres, después de braquiterapia pélvica, en seguimiento en el servicio de fisioterapia. Recopilación de datos a través de entrevistas semiestructuradas, incluyendo datos sociodemográficos y clínicos y el significado del uso de prótesis peneana en la dilatación vaginal, sometidos a análisis de contenido y discutidos a la luz del estudio From 'sex toy' to intrusive imposition. Resultados: el significado impregna el ejercicio de dilatación vaginal; dificultades relacionadas con condiciones vaginales, enfermedad, tratamiento, dolor, sexo, vergüenza, prejuicios, fallas en la educación para la salud; las motivaciones están relacionadas con la búsqueda de calidad de vida, apoyo de la pareja y profesionales. Conclusión: se debe planificar y ejecutar el abordaje de las posibles barreras emocionales, psicológicas, sociales y físicas para prevenir la estenosis vaginal y una mejor recepción.
Subject(s)
Humans , Female , Adult , Middle Aged , Aged , Vagina/radiation effects , Brachytherapy/adverse effects , Uterine Cervical Neoplasms/radiotherapy , Endometrial Neoplasms/radiotherapy , Constriction, Pathologic/rehabilitation , Dilatation/instrumentation , Interviews as Topic , Follow-Up Studies , Qualitative Research , Sociodemographic FactorsABSTRACT
Introduction: there is a great diversity in the profile of cancers in the world. This study set out to analyze the profile of gynecological cancer in Federal University Teaching Hospital, Owerri, [FUTHO] (former Federal Medical Centre, Owerri, Imo state, Nigeria). Methods: this was a retrospective cross sectional descriptive study of the records of women admitted in the gynecological ward in FUTHO from January 2020 to November 2022. It was analyzed using SPSS version 23.0 and reported in simple percentages for categorical variables and measures of central tendency for quantitative variables. Results: a total of 1,378 gynecological patients were admitted into the Gynaecological ward of the hospital, out of which 242 (17.6%) were cancer cases. The most common cancer over the three years in review, was ovarian, 81(33.5%), followed by cervical, 66 (27.3 %), endometrial, 65 (26.8 %), choriocarcinoma, 22 (9.1%), vulvar, 6 (2.5%) and vagina, 2(0.8%). The most common gynecological cancers in this study is very different from previous reports from Nigeria and other African countries. The pattern looks like that seen in the developed countries where endometrial and ovarian cancers top the list. Conclusion: this report shows a possible change in lifestyle and improved access to cervical cancer prevention strategies. It is also assumed that all the facilities who have recorded cervical cancer as the most common cancer can actually have a similar result as ours if a more current review is done.
Subject(s)
Humans , Female , Uterine Neoplasms , Vulvar Neoplasms , Choriocarcinoma , Uterine Cervical Neoplasms , Endometrial Neoplasms , Early Detection of Cancer , Tertiary Care Centers , Epidemiology , Disease PreventionABSTRACT
Introducción: El cáncer de endometrio es la patología oncológica más frecuente en la posmeno-pausia, asociada a hemorragia uterina anormal. Diferentes estudios han encontrado relación significativa entre el grosor endometrial aumentado y el riesgo de cáncer de endometrio. El objetivo del presente estudio fue medir la asociación entre estas variables y realizar pruebas diagnósticas en un centro de referencia regional en Guayaquil-Ecuador. Metodología: El presente estudio analítico, se realizó en el Hospital Ginecológico Obstétrico Pediátrico Universitario de la ciudad de Guayaquil-Ecuador de enero a diciembre del 2018, con una muestra no probabilística, se incluyeron mujeres posmenopáusicas con sangrado uterino y engrosamiento endometrial igual o mayor a 3 milímetros al estudio ecográfico transvaginal y fueron sometidas a legrado con reporte histopatológico. La variable dependiente fue presencia histológica de neoplasia endometrial, la variable independiente fue el grosor endometrial ecográfico. Resultados: El análisis incluyó 148 pacientes, con una edad promedio de 57.9 ± 5.4 años. Obesidad en 22 casos (10.9%), diabetes tipo 2 en 20 casos (9.95%) e hipertensión en 11 casos (5.47%). Fueron 19 casos con cáncer de endometrio y 129 casos con hiperplasia endometrial. El promedio del grosor endometrial fue de 3.560 ± 0.49969 mm. El grosor >3.5 mm OR 54.03 (IC 95% 3.19-914.34) P=0.0057. La sensibilidad del 100%, especificidad 58.1%, valor predictivo positivo de 26.0%, exactitud de 63.5%. Conclusión: La sensibilidad de la medición del grosor endometrial >3.5 mm como predictor de cáncer endometrial en mujeres postmenopáusicas sintomáticas es alta, sin embargo no tiene una buena especificidad y valor predictivo positivo lo que limitan su uso clínico.
Introduction: Endometrial cancer is the most frequent oncological pathology in postmenopause and is associated with abnormal uterine bleeding. Different studies have found a significant relationship between increased endometrial thickness and the risk of endometrial cancer. This study aimed to measure the association between these variables and perform diagnostic tests in a regional reference center in Guayaquil, Ecuador. Methodology: This analytical study was carried out at the University Pediatric-Obstetric-Gynecological Hospital of the city of Guayaquil-Ecuador from January to December 2018, with a nonprobabilistic sample, including postmenopausal women with uterine bleeding and endometrial thickening equal to or greater than 3 millimeters to the transvaginal ultrasound study who were subjected to curettage with a histopathological report. The dependent variable was the histologicalence of endometrial neoplasia; the independent variable was the ultrasound endometrial thickness. Results: The analysis included 148 patients, with a mean age of 57.9 ± 5.4 years. Obesity was observed in 22 cases (10.9%), type 2 diabetes in 20 cases (9.95%), and hypertension in 11 cases (5.47%). There were 19 cases of endometrial cancer and 129 cases of endometrial hyperplasia. The mean endometrial thickness was 3.560 ± 0.49969 mm. Thickness >3.5 mm OR 54.03 (95% CI 3.19-914.34) P=0.0057. The sensitivity was 100%, the specificity was 58.1%, the positive predictive value was 26.0%, and the accuracy was 63.5%. Conclusion: The sensitivity of measuring endometrial thickness >3.5 mm as a predictor of endo-metrial cancer in symptomatic postmenopausal women is high; however, it does not have reasonable specificity or positive predictive value, which limits its clinical use.
Subject(s)
Humans , Endometrial Neoplasms , Endometrium , Uterine Hemorrhage , Odds Ratio , UltrasonographyABSTRACT
Objective: To explore the expression of miR1290 in endometrial cancer tissues and its relationship with the pathological grade, and to find out the effect of miR1290 on biological characteristics of endometrial cancer cells and its mechanism. Methods: A total of 38 cases of endometrioid adenocarcinoma tissues, 10 cases of adjacent tissues and 23 cases of normal endometrial tissues were collected in Provincial Hospital Affiliated to Shandong University from May 2020 to October 2020. The expression of miR1290 was detected by reverse transcription polymerase chain reaction (RT-PCR). The expressions of miR1290 in endometrial cancer cells including KLE and Ishikawa were knocked down by lentiviral transfection. Cell counting kit 8 (CCK-8) test and colony formation test were used to detect cell proliferation ability, wound healing and Transwell test were used to detect cell invasion and migration ability, western blot was used to detect the expressions of epithelial-mesenchymal transition (EMT), phospholipids acylinositide 3-kinase (PI3K)/Akt and Wnt/β-catenin pathway related proteins. Results: The relative expressions of miR1290 in endometrial cancer tissues were 5.40±3.20, which was 1.55 times of normal endometrial tissues (P<0.01) and 1.75 times of adjacent tissues (P<0.01). The relative expressions of miR1290 in 17 cases of endometrial tissues at proliferative stage and 6 cases of endometrial tissues at secretory stage were 3.00±1.08 and 4.97±0.58, respectively, and the difference was statistically significant (P<0.01). In KLE cells and Ishikawa cells, the expression of miR1290 in miR1290 knockdown (Sh-miR1290) group was decreased when compared with the negative control (Sh-NC) group. The absorbance value of Sh-miR1290 group detected by the CCK-8 method and the colony formation rate detected by the colony formation experiment were both increased, the number of cells penetrating the basement membrane in the Transwell experiment and the wound healing rate in the scratch experiment were decreased (P<0.05). In KLE cells, knockdown of miR1290 reduced the expressions of EMT-related proteins including N-cadherin, Vimentin, Snail and Slug(P<0.05), and the expressions of PI3K and P-Akt/Akt (P<0.05), while there was no significant change in the expressions of Wnt and β-catenin (P>0.05). In Ishikawa cells, knockdown of miR1290 decreased the expressions of EMT-related proteins including N-cadherin, Snail and Slug, and the expressions of Wnt and β-catenin, increased the expression of E-cadherin (P<0.05), while there was no significant change in the expressions of PI3K and P-Akt/Akt (P>0.05). Conclusions: The expressions of miR1290 in endometrial cancer tissues are higher than that in the adjacent tissues and normal endometrial tissues. Knockdown of miR1290 expression can promote the proliferation of endometrial cancer cells, but inhibit cell invasion, migration and EMT ability through the PI3K/Akt and Wnt/β-catenin pathways.
Subject(s)
Cell Line, Tumor , Cell Movement , Cell Proliferation , Endometrial Neoplasms/genetics , Epithelial-Mesenchymal Transition , Female , Humans , MicroRNAs/genetics , Phosphatidylinositol 3-Kinases/metabolism , Wnt Signaling PathwayABSTRACT
Introdução: O carcinoma endometrial (CE) foi classificado pelo sistema de Bokhman em tipos I e II com base em observações clínicas e epidemiológicas. O tipo I corresponde aos tumores de baixo grau e o tipo II aos tumores de alto grau. Adicionalmente, estudos recentes propuseram que a classificação também fosse baseada em aspectos histológicos e moleculares com base nos dados do TCGA (The Cancer Genome Atlas). Foram identificados quatro grupos moleculares distintos de CE: (1) com mutações no POLE (fenótipo "ultramutado"), (2) "alto número de cópias" (mutações em TP53), (3) !baixo número de cópias" (em que os tumores não apresentam nenhuma das alterações descritas nos outros tipos) e (4) tumores com predomínio de instabilidade de microssatélites. A imunohistoquímica (IHC) para proteínas do gene de reparo é usada para identificar a deficiência de genes de reparo do DNA (Mismatch Repair MMR) associada à instabilidade de microssatélites(MSI). A coloração nuclear positiva representa a expressão retida de proteínas MMR, enquanto a perda completa representa deficiência de MMR. O padrão de expressão heterogênea (HEP), ou seja, concomitância em um mesmo espécime de áreas positivas e totalmente negativas tem sido observada em CE. No presente momento, as principais diretrizes determinam que a presença de HEP seja interpretada como expressão retida de proteínas MMR. Não há, porém, consenso quanto à classificação e interpretação de HEP, nem conhecimento do impacto da classificação de HEP como subtipo molecular diferente em relação às características clínicas e prognósticas. Objetivos: realizar a classificação molecular dos casos de CE com HEP das proteínas relacionadas aos genes de reparo do DNA e comparação do perfil molecular entre áreas positivas e negativas no estudo imunohistoquímico. Materiais e Métodos: De janeiro/2007 a dezembro/2017 foram identificados 356 casos de CE, 16 deles com HEP. A classificação molecular foi feita com base no protocolo PROMISE para CE. Cada área (expressão retida ou perdida) foi macrodissecada e o status molecular foi avaliado separadamente quanto ao status MSI (Idylla), metilação do promotor MLH1 (NGS - ponto de corte para positividade ≥ 15%), status POLE (NGS) e status p53 (IHC). Variáveis clínicas e patológicas também foram avaliadas e correlacionadas com cada caso. Resultados: A histologia endometrioide foi predominante (15 casos), bem como ausência de invasão linfovascular (11 casos), ausência de padrão MELF (10 casos), graus FIGO 1 e 2 (13 casos), invasão miometrial < 50% (13 casos) e estadiamento T1 (13 casos). Todos os pacientes estavam vivos e sem evidência de doença no último acompanhamento, exceto por um caso, cujo status de sobrevida era desconhecido. Dois casos que seriam descritos como apresentando expressão retida de proteínas relacionadas a genes de reparo do DNA por IHC apresentaram-se na análise molecular com instabilidade de microssatélites(MSI-H). Nos casos de HEP, a proteína MSH6 foi a maisfrequentemente envolvida (9 casos, 7 isolados). A proteína MLH1 apresentou-se alterada em 6 casos, sendo a única proteína associada a co-alterações (com MSH6 e PMS2). Seis casos apresentaram-se metilados por MLH1, padrão encontrado tanto em áreas com perda quanto em áreas com retenção das proteínas relacionadas a MMR por IHC e dois casos apresentaram metilação em apenas uma das áreas. Em relação ao status de POLE, 6 casos apresentaram mutação, 2 com mutações tanto em áreas com perda quanto em áreas com retenção de expressão, 3 apenas na área com perda e 1 apenas na área com retenção. Dois casos apresentam padrão aberrante de p53 (MSH6 alterados) em ambas as áreas. Conclusão: em pacientes portadoras CE e com tumores apresentando HEP a correlação entre a IHC e os achados moleculares é heterogênea e o diagnóstico entre casos com retenção ou das proteínas relacionadas a MMR não é factível apenas com realização de IHC. A análise molecular deve ser realizada em todos os casos de CE com HEP para determinar adequadamente as característicasintrínsecas de cada tumor. Devido à raridade desse achado, esta proposta é financeiramente viável e tem o potencial de mudar a prática clínica em um subconjunto de pacientes, permitindo tratamentos inovadores. HEP deve ser relatado como um padrão distinto e não considerado como uma expressão sinônimo de expressão retida de proteínas MMR em CE.
Introduction: Endometrial adenocarcinoma is classified by the Bokhman system in type I and II based on clinical and epidemiological observations, whereas the type I represents low grade tumors and type II high grade tumors. Additionally, a classification based on histological aspects and molecular profile has been proposed. The TCGA (The Cancer Genome Atlas) identified four molecular groups of endometrial adenocarcinomas: (1) mutations in POLE ("ultramutated" phenotype), (2) "high copy number" (mutations in TP53), (3) "low number of copies " (in which the tumors do not exhibit any of the changes described in the other types) and (4) tumors with predominance of microsatellite instability. In a small number of patients, heterogeneous staining is observed in the evaluation protein expression for mismatch repair genes. Objectives: to evaluate and perform the molecular classifications of cases of endometrial carcinoma with heterogeneous staining by IHC of proteins related to mismatch repair genes and comparison of the molecular profile of positive and negative areas in the IHC study. Cases and Methods: From January/2007 to December/2017 354 cases with EC were identified, 16 of those with HEP. Molecular classification was made based on the PROMISE protocol for EC. Each area (retained and lost expression) was macrodissected and molecular status was evaluated separately regarding MSI status (Idylla), MLH1 promoter methylation (NGS - cutoff for positivity ≥ 15%), POLE status (NGS) and p53 status (IHC). Clinical and pathologic variables were also evaluated and correlated with each case. Results: Endometrioid histology was predominant (15 cases), as absent lymphovascular invasion (11 cases), absence of MELF pattern (10 cases), FIGO Grade 1 and 2 (13 cases), and T1 stage (13 cases). All patients were alive and disease-free at the last follow-up. Two cases that would be described as retained by IHC presented in the molecular analysis as MSI-H. In HEP cases MSH6 was more frequent (9 cases, 7 isolated). MLH1 was altered in 6 cases, and wasthe only protein associated with co-alterations (with MSH6 and PMS2). Six cases were MLH1 methylated, found both in lost and retained areas. As POLE status, there were 6 mutated cases, 2 of those with mutations both in lost and retained areas, and 3 the lost area. Two cases had p53 aberrant pattern (MSH6 altered), that was seen both in the retained and in the lost areas. Conclusion: Correlation between IHC and molecular findings is heterogeneous, and determination between retained or lost expression of MMR proteins by IHC when HEP occurs, however feasible, does not represent the actual molecular alterations. Thus, molecular analysis should be performed every case to adequately determine the intrinsic features of each tumor. Due to the rarity of this finding, this is financially viable and has the potential to change clinical practice in a subset of patients. HEP should be reported as a distinct pattern, and not considered as a synonym expression of retained expression of MMR proteins in EC.
Subject(s)
Humans , Female , Adenocarcinoma/genetics , Gene Expression/genetics , Endometrial Neoplasms/genetics , DNA Repair/genetics , Immunohistochemistry , Retrospective StudiesABSTRACT
Background and Objective@#Radical hysterectomy remains to be the first surgery for early‑stage cervical and selected stage 2 endometrial carcinoma. Functional disorders of the lower urinary tract are the foremost common complications following radical surgery necessitating catheterization. This study was undertaken to determine the number of postoperative days (POD) of the removal of urinary catheters after hysterectomy and assess the practicability of earlier removal of the catheter without compromising the bladder function@*Methodology@#A descriptive observational study of patients who underwent Type 2 or 3 hysterectomy for cervical or endometrial carcinoma. Clinical, intraoperative, and anesthesia records and results of the histopathologic reports of every patient were reviewed. Demographic, clinical, and histopathologic data needed during this review were recorded. Descriptive statistics were used.@*Results@#Between January 2016 and December 2019, a complete 45 patients underwent radical hysterectomy (43 patients for cervical cancer and a pair for endometrial carcinoma), with a median age of 50 years. The mean operative time is 2.5 h and also the average blood loss is 500 ml. The mean size of the cervical tumor was 2.2 cm, the mean length of the vagina was 2.5 cm, and the mean lateral width of parametria was 3.6 cm. Catheters were removed between the 3rd and 20th (mean = 6 days) POD. All patients had adequate spontaneous void within 6 h after removal. Five patients had their catheters removed beyond 7 days, 3 patients between POD 8 and POD 14, and 2 patients between days POD 15 and POD 20. All patients were able to return to bladder function within 3 weeks of catheterization.@*Conclusion@#The outcome showed that earlier removal of catheter seems to be a practical and safe option compared to long‑term catheterization for patients who underwent radical hysterectomy without causing morbidities
Subject(s)
Uterine Cervical Neoplasms , Endometrial NeoplasmsABSTRACT
YWHAE gene is located on chromosome 17p13.3, and its product 14-3-3epsilon protein belongs to 14-3-3 protein family. As a molecular scaffold, YWHAE participates in biological processes such as cell adhesion, cell cycle regulation, signal transduction and malignant transformation, and is closely related to many diseases. Overexpression of YWHAE in breast cancer can increase the ability of proliferation, migration and invasion of breast cancer cells. In gastric cancer, YWHAE acts as a negative regulator of MYC and CDC25B, which reduces their expression and inhibits the proliferation, migration, and invasion of gastric cancer cells, and enhances YWHAE-mediated transactivation of NF-κB through CagA. In colorectal cancer, YWHAE lncRNA, as a sponge molecule of miR-323a-3p and miR-532-5p, can compete for endogenous RNA through direct interaction with miR-323a-3p and miR-532-5p, thus up-regulating K-RAS/ERK/1/2 and PI3K-AKT signaling pathways and promoting the cell cycle progression of the colorectal cancer. YWHAE not only mediates tumorigenesis as a competitive endogenous RNA, but also affects gene expression through chromosome variation. For example, the FAM22B-YWHAE fusion gene caused by t(10; 17) (q22; p13) may be associated with the development of endometrial stromal sarcoma. At the same time, the fusion transcript of YWHAE and NUTM2B/E may also lead to the occurrence of endometrial stromal sarcoma. To understand the relationship between YWHAE, NUTM2A, and NUTM2B gene rearrangement/fusion and malignant tumor, YWHAE-FAM22 fusion gene/translocation and tumor, YWHAE gene polymorphism and mental illness, as well as the relationship between 17p13.3 region change and disease occurrence. It provides new idea and basis for understanding the effect of YWHAE gene molecular mechanism and genetic variation on the disease progression, and for the targeted for the diseases.
Subject(s)
14-3-3 Proteins/metabolism , Breast Neoplasms/genetics , Cell Line, Tumor , Cell Proliferation/genetics , Cell Transformation, Neoplastic/genetics , Colorectal Neoplasms/genetics , Endometrial Neoplasms , Female , Gene Expression Regulation, Neoplastic , Humans , MicroRNAs/genetics , Phosphatidylinositol 3-Kinases/metabolism , Sarcoma, Endometrial Stromal/pathology , Stomach Neoplasms/genetics , Transcription Factors/genetics , Translocation, GeneticABSTRACT
Objective: To analyze the clinical efficacy of fertility-preserving therapy in patients with atypical endometrial hyperplasia (AEH) and early endometrial carcinoma (EC). Methods: The general condition, pathological type, treatment plan, tumor outcomes and pregnancy outcomes of 110 patients with AEH and EC treated with fertility-preserving therapy in Peking University People's Hospital from December 2005 to September 2019 were retrospectively analyzed. Kaplan-Meier and Log rank tests were used for survival analysis. Results: The response rate of 110 cases of AEH (62 cases) and EC (48 cases) was 94.5% (104/110) after fertility-preserving therapy. There were 93 cases (84.5%) achieved complete response and 11 cases (10.0%) achieved partial response, and the recurrence rate was 29.0% (27/93). The complete response rates of AEH and EC were 90.3% (56/62) and 77.1% (37/48), respectively, without significant difference (P=0.057). The recurrence rates of EC were significantly higher than that of AEH (40.5% vs 21.4%; P=0.022). Forty-one patients with complete response had pregnancy intention, the pregnancy rate was 70.7% (29/41), and the live birth rate was 56.1% (23/41). The live birth rate of AEH was 68.2% (15/22) and that of EC was 42.1% (8/19), the difference was statistically significant (P=0.032). The pathological type was related with the recurrence (P=0.044). Conclusions: Patients with AEH and EC can obtain high complete response rate and pregnancy rate after fertility-preserving therapy. The recurrence rate of EC is higher than that of AEH, while the live birth rate of AEH is higher than that of EC.
Subject(s)
Endometrial Hyperplasia/surgery , Endometrial Neoplasms/surgery , Female , Fertility , Fertility Preservation , Humans , Pregnancy , Retrospective StudiesABSTRACT
Introducción. El carcinoma de endometrio es una patología heterogénea a nivel patogénico, histopatológico y molecular. En los últimos años se han sumado esfuerzos para esclarecer y aumentar el conocimiento de las bases moleculares, logrando así dividir las pacientes en cuatro subgrupos descritos por el Atlas del Genoma del Cáncer (TCGA, por sus siglas en inglés), obteniéndose valiosa información que afecta el diagnóstico, tratamiento y pronóstico de las pacientes con esta enfermedad. El objetivo de la siguiente revisión es exponer la nueva clasificación molecular del carcinoma de endometrio, así como discutir las ventajas que esta trae a la hora de estratificar a las pacientes y tomar decisiones terapéuticas. División de los temas tratados. Se realizó una búsqueda bibliográfica no sistemática en las bases de datos PubMed, Cochrane y Medline desde el año 2014 hasta el 2020 sobre el carcinoma de endometrio y su clasificación molecular. Se expone de manera concreta y actualizada el contexto histórico, los diferentes subgrupos moleculares y cómo estos impactan en el manejo de las pacientes. Conclusiones. El carcinoma de endometrio es una enfermedad heterogénea a nivel histopatológico, clínico y molecular. Con la nueva clasificación y los estudios prospectivos se podrán crear nuevas estrategias que permitan brindar mejores protocolos diagnósticos y terapéuticos.
Introduction. Endometrial carcinoma is a heterogeneous pathology in pathologenic, histopathological, and molecular terms. Over the last years, efforts have been made to clarify and increase knowledge of molecular bases, as such dividing patients into four subgroups described by the The Cancer Genome Atlas (TCGA), obtaining valuable information that affects the diagnosis, treatment, and prognosis of patients with this disease. The objective of this review is to exhibit the new molecular classification of endometrial carcinoma, and to discuss its advantages when stratifying patients and making therapeutic decisions. Division of Covered Topics. A non-systematic bibliographical search was carried out in the PubMed, Cochrane, and Medline databases from 2014 to 2020, on endometrial carcinoma and its molecular classification. The historical context, different molecular subgroups and how these impact patient handling are shown in a concrete and updated way. Conclusions. Endometrial carcinoma is a heterogeneous disease in histopathological, clinical, and molecular terms. With the new classification and the prospective studies, new strategies can be created to provide better diagnostic and therapeutic protocols.
Introdução. O carcinoma de endométrio é uma patologia heterogênea no nível patogênico, histopatológico e molecular. Nos últimos anos, foram feitos esforços para esclarecer e aumentar o conhecimento das bases moleculares, conseguindo dividir as pacientes em quatro subgrupos descritos pelo Atlas do Genoma do Câncer (TCGA, por suas siglas em inglês), obtendo informações valiosas que afetam o diagnóstico, o tratamento e o prognóstico das pacientes com esta doença. O objetivo da seguinte revisão é apresentar a nova classificação molecular do carcinoma de endométrio, bem como discutir as vantagens que ela traz no momento de estratificar as pacientes e tomar decisões terapêuticas. Divisão dos tópicos abordados. Uma pesquisa bibliográfica não sistemática foi realizada nas bases de dados PubMed, Cochrane e Medline de 2014 a 2020 sobre o carcinoma de endométrio e sua classificação molecular. São apresentados de forma concreta e atualizada o contexto histórico, os diferentes subgrupos moleculares e como esses têm impacto no tratamento das pacientes. Conclusões. O carcinoma de endométrio é uma doença heterogênea no nível histopatológico, clínico e molecular. Com a nova classificação e estudos prospectivos, novas estratégias podem ser desenvolvidas para fornecer melhores protocolos diagnósticos e terapêuticos.
Subject(s)
Endometrial Neoplasms , Prognosis , Immunohistochemistry , Carcinoma , Genome , EndometriumABSTRACT
Os contraceptivos intrauterinos contendo levonorgestrel, Mirena®, amplamente utilizados na ginecologia contemporânea como método eficaz de contracepção e controle de distúrbios menstruais, mostrou reduzir as taxas de câncer de endométrio. Além disso, complicações como perfuração e migração são raras, exigindo intervenção rápida. Descrição: Dois casos atípicos acerca do uso de dispositivo intrauterino hormonal, o primeiro trata de migração do dispositivo para a cavidade abdominal, após 1 ano e 8 meses da inserção, sem perfuração, com retirada videolaparoscópica. O segundo é um caso de câncer primário de endométrio em paciente com 3 anos de uso de Mirena®. Discussão: A migração do dispositivo intrauterino é uma complicação rara, pouco relatada na literatura, a abordagem videolaparoscópica é a preferencial e foi realizada no caso em questão. O dispositivo intrauterino hormonal também está relacionado à diminuição das taxas de câncer de endométrio e, inclusive, é usado como método preventivo em mulheres de alto risco. Após revisão de literatura, apenas seis casos similares foram descritos. Conclusão: O dispositivo hormonal intrauterino, apesar de seguro, pode implicar apresentações raras, como migração e perfuração, que exigem conhecimento e agilidade da equipe profissional. O segundo caso apresentado é um evento raro, que faz atentar para mulheres com padrão hemorrágico incomum em uso do Mirena®. (AU)
Intrauterine contraceptives containing levonorgestrel, Mirena®, widely used in contemporary gynecology as an effective method of contraception and control of menstrual disorders, have shown to reduce rates of endometrial cancer. In addition, complications such as perforation and migration are rare, requiring rapid intervention. Description: Two atypical cases about the use of intrauterine hormonal device, the first deals with migration of the device to the abdominal cavity, after 1 year and 8 months of insertion, without perforation, with videolaparoscopic withdrawal. The second is a case of primary endometrial cancer in a patient with 3 years of use of Mirena®. Discussion: Migration of the intrauterine device is a rare complication, little reported in the literature, the videolaparoscopic approach is the preferred one and was performed in the case in question. The hormonal intrauterine device is also related to the decreased rates of endometrial cancer and is also used as a preventive method in high-risk women. After reviewing the literature, only six similar cases were described. Conclusion: The intrauterine hormonal device, although safe, may imply rare presentations, such as migration and perforation, which require knowledge and agility of the professional team. The second case presented is a rare event, which makes it aware for women with an unusual hemorrhagic pattern to use Mirena®. (AU)
Subject(s)
Humans , Female , Adult , Levonorgestrel , Endometrial Neoplasms , Contraception , Contraceptive Agents , Intrauterine Devices , Menstruation DisturbancesABSTRACT
Introducción: El cáncer de endometrio, el cáncer de ovario y el cáncer cervicouterino son las neoplasias, dentro del cáncer del aparato reproductor femenino, que se consideran más frecuentes en la actualidad. La aparición de cáncer ginecológico en mujeres vírgenes demuestra que se deben consideran otras factores causales de la enfermedad, sin embargo, en nuestro país, no hay la suficiente evidencia de documentación sobre estos casos. El objetivo del presente estudio medir la prevalencia de cáncer de cuello uterino, útero y ovarios en mujeres vírgenes atendidas en un centro de referencia de Ginecología Oncológica de Guayaquil. Metodología: El estudio es observacional y transversal, se realizó en el Hospital de Especialidades Teodoro Maldonado Carbo, del Instituto Ecuatoriano de Seguridad Social, Guayaquil-Ecuador, de enero del 2013 al diciembre del 2017. Se incluyeron pacientes con cáncer cervicouterino, de útero y ovarios divididos en Grupo 1 (G1) Mujeres vírgenes y Grupo 2 (G2): Mujeres con vida sexual activa. Las variables fueron edad, órgano afectado, comorbilidades, antecedente familiar de cáncer, tipo histológico y muerte. La muestra fue no probabilística, tipo censo. Se utiliza estadística analítica, la muestra dividida en 2 grupos se compara usando Chi2. Se reporta Odds Ratio con intervalo de confianza del 95%. Resultados: En G1 fueron 44 casos y en G2 fueron 337 casos. Lo que representa una prevalencia de 11.55% (IC95% 11.38-11.71%). Cáncer de Ovario en G1 fue 29/44 casos (66%) versus 95/337 casos (28.2%) en G2 P<0.0001 con OR: 4.92 (2.53-9.60). Cáncer de endometrio en G1 13/44 casos (29.5%) versus 54/337 casos (16%) en G2, OR 2.20 (1.08-4.47) P=0.03. Cáncer cervical en G1 2/44 casos (4.5%) y en G2 188/337 casos (55.8%) OR 0.38 (0.009-0.159) P<0.0001. La mortalidad en G1 fue 30/44 casos en G2 fue 130/337 casos, OR 4.14 (2.12-8.08) P>0.0001. Conclusión: En mujeres sin antecedentes de vida sexual, existe mayor riesgo de cáncer de ovario y de endometrio y el riesgo de cáncer de cérvix se disminuye un 96%. La mortalidad de este grupo de mujeres se duplica por la mayor existencia de cáncer de ovario y endometrial.
Introduction: Endometrial cancer, ovarian cancer and cervical cancer are the neoplasias, within cancer of the female reproductive system, which are considered more frequent today. The appearance of gynecological cancer in virgin women shows that other causal factors of the disease must be considered, however, in our country, there is not enough documentary evidence on these cases. The objective of this study is to measure the prevalence of cervical, uterine and ovarian cancer in virgin women treated in a reference center for Gynecology Oncology in Guayaquil. Methodology: The study is observational and cross-sectional, it was carried out at the Teodoro Maldonado Carbo Specialties Hospital, of the Ecuadorian Social Security Institute, Guayaquil-Ecuador, from January 2013 to December 2017. Patients with cervical, uterine and cervical cancer were includ-ed. ovaries divided into Group 1 (G1) Virgin women and Group 2 (G2): Women with an active sexual life. The variables were age, affected organ, comorbidities, family history of cancer, histological type, and death. The sample was non-probabilistic, census type. Analytical statistics are used, the sample divided into 2 groups is compared using Chi2. Odds Ratio is reported with a confidence interval of 95%. Results: In G1 there were 44 cases and in G2 there were 337 cases. Which represents a prevalence of 11.55% (95% CI 11.38-11.71%). Ovarian cancer in G1 was 29/44 cases (66%) versus 95/337 cases (28.2%) in G2 P <0.0001 with OR: 4.92 (2.53-9.60). Endometrial cancer in G1 13/44 cases (29.5%) versus 54/337 cases (16%) in G2, OR 2.20 (1.08-4.47) P = 0.03. Cervical cancer in G1 2/44 cases (4.5%) and in G2 188/337 cases (55.8%) OR 0.38 (0.009-0.159) P <0.0001. Mortality in G1 was 30/44 cases in G2 it was 130/337 cases, OR 4.14 (2.12-8.08) P> 0.0001. Conclusion: In women with no history of sexual life, there is a greater risk of ovarian and endometrial cancer and the risk of cervical cancer is decreased by 96%. The mortality of this group of women doubles due to the increased existence of ovarian and endometrial cancer
Subject(s)
Humans , Female , Sexual Behavior , Uterine Cervical Neoplasms , Endometrial Neoplasms , Ovarian Neoplasms , Parity , Uterine NeoplasmsABSTRACT
RESUMEN Objetivo. Estimar la incidencia, mortalidad y supervivencia a cinco años por carcinoma endometrial en Manizales, para el periodo 2003-2017. Materiales y métodos. Estudio observacional, retrospectivo, de base poblacional, con alcance descriptivo. Se ajustaron tasas de incidencia y mortalidad mediante el método directo usando la población mundial Segi como referencia. Se realizó seguimiento pasivo y activo de los casos hasta completar 60 meses o hasta la fecha de cierre de seguimiento. La supervivencia fue estimada mediante funciones de Kaplan-Meier y modelos de regresión de Cox. Resultados. Se observaron 210 casos incidentes en una población de 214 928 mujeres. La edad promedio al diagnóstico fue de 61 años. El tipo histológico más frecuente fue el endometrioide, bien diferenciado. La mayoría de las pacientes estaban afiliadas al régimen contributivo y pertenecían al nivel socioeconómico medio. La tasa de incidencia ajustada por edad fue de 5,7 casos nuevos por cada 100 000 mujeres-año. Se identificaron 75 defunciones con mayor mortalidad entre los 64 y los 79 años. La supervivencia global fue de 95,1% a los 12 meses y de 83,8% a los 60 meses. Se encontraron diferencias estadísticamente significativas en la supervivencia a favor de la histología epitelial, los estadios tempranos al momento del diagnóstico y la edad al diagnóstico menor a 60 años. Conclusiones. La mortalidad es similar a la reportada en otros países de la región. En Manizales, la sobrevida al cáncer de endometrio fue mayor en pacientes con diagnóstico temprano, con edad menor de 60 años y con histología endometrioide.
ABSTRACT Objective. To estimate the incidence, mortality and five-year survival of endometrial carcinoma in Manizales for the period 2003-2017. Materials and methods. Observational, retrospective, population-based study, descriptive in scope. Incidence and mortality rates were adjusted by the direct method using the Segi world population as reference. Passive and active follow-up of the cases was carried out until completing 60 months or until the follow-up closing date. Survival was estimated using Kaplan-Meier functions and Cox models. Results. 210 incident cases were observed in a population of 214.928 women. The average age at diagnosis was 61 years. The most frequent histological type was endometrioid, well differentiated. Most of the patients were affiliated to the contributory health insurance scheme and belonged to the middle socioeconomic level. The age-adjusted incidence rate was 5.7 new cases per 100,000 woman-years. Seventy-five deaths were identified, with greater mortality between 65-69 and 75-79 age groups. Overall survival was 95.1% at 12 months and 83.8% at 60 months. Statistically significant differences were found in survival in favor of epithelial histology, early stages at the time of diagnosis, and age at diagnosis less than 60 years. Conclusions. Manizales follows the global pattern of rise in the age-adjusted incidence rate. Mortality is like that reported in other countries in the region. In Manizales, endometrial cancer survival was higher in patients with early diagnosis, less than 60 years of age, and with endometrioid histology.
Subject(s)
Humans , Female , Survival , Incidence , Mortality , Neoplasms , Epidemiology , Vital Statistics , Endometrial Neoplasms , ColombiaABSTRACT
ABSTRACT: Endometrial carcinoma is a very rare cause of cutaneous metastasis.The most frequent presentations of cutaneous metastasis are fast developing nodules or tumors, which are evi-dence of widespread dissemination in such patients.We report a case of scalp metastasis from an endometrial adenocarcinoma with a fatal prognosis. (AU)
RESUMO: O carcinoma endometrial é uma causa rara de metástases cutâneas.A apresentação mais frequente de metástases cutâneas são nódulos ou tumores de rápido desenvolvimento, que evidenciam uma disseminação generalizada nesses pacientes.Relatamos um caso de metástase no couro cabeludo de um adenocarcinoma endometrial com prognóstico fatal. (AU)
Subject(s)
Humans , Aged , Prognosis , Scalp , Adenocarcinoma , Endometrial Neoplasms , Neoplasm MetastasisABSTRACT
Introducción: El trombo embolismo venoso (TEV), una complicación frecuente en pacientes con cáncer ginecológico. El objetivo del estudio fue determinar la incidencia de TEV profunda en pacientes diagnosticados con neoplasias útero ováricas en un centro de referencia oncológica en Guayaquil-Ecuador en el año 2019 (enero-diciembre). Metodología: El presente estudio observacional, de fuente retrospectiva se realizó en el servicio de estadística del Instituto Oncológico Nacional "Dr. Juan Tanca Marengo" de la Sociedad de Lucha contra el Cáncer-SOLCA, Guayaquil Ecuador. El cálculo del tamaño muestral fue probabilístico de 237 pacientes. Se incluyeron casos de pacientes con neoplasias útero ováricas y endometriales. Las variables fueron edad, localización de la neoplasia, incidencia de TEV en base a evidencia Ultrasonográfica de TEV, criterios Wels, dímero D. Se utilizó estadística descriptiva. Los porcentajes se presentan con intervalo de confianza. Resultados: Se incluyeron 237 pacientes, el grupo etario más frecuente de 40 a 59 años con el 46.4%, seguido de 60 y más años con el 34.6%; el 88.6% de los casos tuvieron cáncer de útero (cérvix endometrio) y el 11.4% con cáncer de ovario. Por la clasificación de Wells, el 92% presentó riesgo moderado de TVP y 8% riesgo alto. La incidencia de trombosis venosa profunda en pacientes con cáncer útero ovario fue del 6.75% (IC 6.54-6.96%). La incidencia fue estadísticamente más prevalente (P=0.01) en el grupo de mujeres con Ca de Útero que en el grupo de Ca de ovario. Conclusión: Las neoplasias útero ováricas tienen alta incidencia de trombosis venosa profunda.
Introduction: Venous thrombus embolism (VTE), a frequent complication in patients with gynecological cancer. The objective of the study was to determine the incidence of deep VTE in patients diagnosed with uterine-ovarian neoplasms in an oncology referral center in Guayaquil-Ecuador in 2019. Methodology: The present observational study, from a retrospective source, was carried out in the statistics service of the National Oncological Institute "Dr. Juan Tanca Marengo" from the Society for the Fight Against Cancer-SOLCA, Guayaquil Ecuador. The calculation of the sample size was probabilistic of 237 patients. Cases of patients with uterine-ovarian and endometrial neoplasms were included. The variables were age, location of the neoplasm, incidence of VTE based on ultrasound evidence of VTE, Wels criteria, D-dimer. Descriptive statistics were used. The percentages are presented with a confidence interval. Results: 237 patients were included, the most frequent age group 40 to 59 years with 46.4%, fol-lowed by 60 and over with 34.6%; 88.6% of the cases had uterine cancer (cervix - endometrium) and 11.4% with ovarian cancer. According to the Wells classification, 92% had a moderate risk of DVT and 8% had a high risk. The incidence of deep vein thrombosis in patients with uterine-ovarian cancer was 6.75% (CI 6.54-6.96%). The incidence was statistically more prevalent (P=0.01) in the group of wom-en with Uterus Ca than in the ovarian Ca group. Conclusion: Utero-ovarian neoplasms have a high incidence of deep vein thrombosis.
Introdução: Embolia por trombo venoso (TEV), uma complicação frequente em pacientes com câncer ginecológico. O objetivo do estudo foi determinar a incidência de TEV profundo em pacientes com diagnóstico de neoplasias uterino-ovarianas em um centro de referência em oncologia em Guayaquil-Equador em 2019 (janeiro-dezembro). Metodologia: O presente estudo observacional, de fonte retrospectiva, foi realizado no serviço de estatística do Instituto Oncológico Nacional "Dr. Juan Tanca Marengo "da Sociedade de Luta contra o Câncer-SOLCA, Guayaquil, Equador. O cálculo do tamanho da amostra foi probabilístico de 237 pacientes. Foram incluídos casos de pacientes com neoplasias uterino-ovarianas e endometriais. As variáveis ââforam idade, localização da neoplasia, incidência de TEV com base em evidências ultrassonográficas de TEV, critérios de Wels, dímero D. Foi utilizada estatística descritiva. As porcentagens são apresentadas com intervalo de confiança. Resultados: foram incluídos 237 pacientes, a faixa etária mais frequente de 40 a 59 anos com 46,4%, seguida de 60 e mais anos com 34,6%; 88,6% dos casos tiveram câncer de útero (colo do útero - endométrio) e 11,4% de câncer de ovário. De acordo com a classificação de Wells, 92% apresentaram risco moderado de TVP e 8% risco alto. A incidência de trombose venosa profunda em pacientes com câncer de útero-ovário foi de 6,75% (IC 6,54-6,96%). A incidência foi estatisticamente mais prevalente (P = 0,01) no grupo de mulheres com Ca no útero do que no grupo de Ca ovariana. Conclusão: As neoplasias útero-ovarianas apresentam alta incidência de trombose venosa profunda.
Subject(s)
Humans , Female , Adult , Middle Aged , Ovarian Neoplasms , Uterine Cervical Neoplasms , Endometrial Neoplasms , Venous Thrombosis , Embolism and ThrombosisABSTRACT
SUMMARY OBJECTIVE: This study aims to analyze inflammatory markers among patients with endometrial cancer, hyperplasia with atypia/endometrial intraepithelial neoplasia, hyperplasia without atypia, and normal controls, thus observing the stage at which inflammation becomes the most significant. METHODS: A total of 444 patients who had endometrial sampling were included in the study (endometrial cancer, n=79; endometrial hyperplasia with atypia/endometrial intraepithelial neoplasia, n=27; endometrial hyperplasia without atypia, n=238; and normal controls, n=100). Neutrophil count, lymphocyte count, platelet count, platelet distribution width, neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, CA-125, and endometrial thickness of the patients were recorded. RESULTS: Comparing the groups for neutrophil count, the hyperplasia with atypia group had higher values compared with both the hyperplasia without atypia group and the control group (p=0.003). When compared for the lymphocyte count, the hyperplasia with atypia group had lower values compared with the control group (p=0.014). Neutrophil/lymphocyte ratio of the hyperplasia with atypia group was higher than all other groups, and neutrophil/lymphocyte ratio of the cancer group was higher than the control group (p=0.001). Platelet count, mean platelet volume, platelet distribution width, and platelet/lymphocyte ratio values were not significantly different among groups (p>0.05). CONCLUSIONS: Considering the inflammatory markers, the most prominent result was that the hyperplasia with atypia group had neutrophilia, lymphopenia, and increased neutrophil/lymphocyte ratio compared with other groups.
Subject(s)
Humans , Female , Endometrial Neoplasms , Endometrial Hyperplasia , Retrospective Studies , Lymphocyte Count , HyperplasiaABSTRACT
Resumen El cáncer de endometrio es la neoplasia ginecológica maligna más frecuente en el sexo femenino. Su presentación metastásica se limita principalmente a los órganos vecinos y ganglios cercanos, y es infrecuente la invasión al tubo digestivo superior. En el presente artículo se presenta una paciente que ingresó al servicio de urgencias con cuadro de hemorragia de vías digestivas altas, enfocado inicialmente como un tumor estromal gastrointestinal (GIST) de la pared gástrica, pero que luego de la realización de una adecuada historia clínica, complementada con imágenes diagnósticas y avances ecoendoscópicos, se logró el diagnóstico de metástasis de cáncer de endometrio.
Abstract Endometrial cancer is the most common gynecologic malignancy in women. Its metastatic presentation is mainly limited to neighboring organs and nearby lymph nodes, and infiltration of the upper digestive tract is uncommon. This case report depicts a patient admitted to the emergency department with upper gastrointestinal bleeding symptoms. Initially, a gastrointestinal stromal tumor (GIST) of the gastric wall was suspected, but endometrial cancer metastasis was discovered after a thorough medical examination, diagnostic imaging, and echoendoscopes.
Subject(s)
Humans , Female , Aged , Endometrial Neoplasms , Gastrointestinal Tract , Gastrointestinal Stromal Tumors , Hemorrhage , Neoplasm Metastasis , WomenABSTRACT
Abstract Objective To evaluate the presence of residual disease in the uterine specimen after hysteroscopic polypectomy or polyp biopsy in patients with endometrioid endometrial cancer (EC). Methods We analyzed a series of 104 patients (92 cases from the Hospital AC Camargo and 12 from the Hospital do Servidor Público Estadual de São Paulo) with polyps that were diagnosed by hysteroscopy, showing endometrioid EC associated with the polyp or in the final pathological specimen. Patients underwent a surgical approach for endometrial cancer from January 2002 to January 2017. Their clinical and pathological data were retrospectively retrieved from the medical records. Results In78cases (75%), thepolyphad EC, and in 40(38.5%), itwas restricted tothe polyp, without endometrial involvement. The pathologic stage was IA in 96 cases (92.3%) and 90 (86.5%) had histologic grade 1 or 2. In 18 cases (17.3%), there was no residual disease in the final uterine specimen, but only in 9 of them the hysteroscopy suggested that the tumor was restricted to the polyp. In 5 cases (4.8%) from the group without outside of the polyp during hysteroscopy, myometrial invasion was noted in the final uterine specimen. This finding suggests the possibility of disease extrapolation through the base of the polyp. Conclusion Patients with endometrioid EC associated with polyps may have the tumor completely removed during hysteroscopy, but the variables shown in the present study could not safely predict which patient would have no residual disease.
Resumo Objetivo Avaliar a presença de doença residual no exame anatomopatológico definitivo de pacientes com câncer de endométrio endometrioide após polipectomia ou biópsia de pólipo histeroscópica. Métodos Analisamos 104 pacientes (92 casos do Hospital AC Camargo e 12 casos do Hospital do Servidor Público Estadual de São Paulo) com pólipos diagnosticados durante histeroscopia e cuja biópsia histeroscópica ou exame patológico final do útero acusaram câncer de endométrio endometrioide. As pacientes foram submetidas a cirurgia para câncer de endométrio de janeiro de 2002 a janeiro de 2017. Os dados clínicos e anatomopatológicos de cada paciente foram retirados dos prontuários médicos Resultados Em 78 casos (75%), o pólipo continha a neoplasia, e em 40 (38.5%), ela estava restrita ao tecido do pólipo, sem envolvimento endometrial adjacente. O estadio final foi IA em 96 casos (92.3%) e em 90 (86.5%) tratava-se de grau 1 ou 2. Em 18 casos (17.3%), não havia doença residual no espécime uterino, mas emapenas 9 deles a histeroscopia sugeriu doença restrita ao pólipo. Em 5 casos (4.8%), não havia doença aparente extrapólipo na histeroscopia, mas havia invasão miometrial, sugerindo extravasamento do tumor pela base do pólipo. Conclusão Pacientes com câncer de endométrio associado a pólipos podem ter o tumor completamente removido durante a histeroscopia, mas, com as variáveis avaliadas, é difícil predizer com segurança qual paciente ficará sem tumor residual.
Subject(s)
Humans , Female , Polyps/surgery , Endometrial Neoplasms/surgery , Carcinoma, Endometrioid/surgery , Neoplasm, Residual/surgery , Neoplasm Recurrence, Local/surgery , Polyps/pathology , Hysteroscopy , Endometrial Neoplasms/pathology , Carcinoma, Endometrioid/pathology , Neoplasm, Residual/pathology , Middle Aged , Neoplasm Recurrence, Local/pathologyABSTRACT
Abstract Objective The aim of the present study was to analyze relapse rates and patterns in patients with endometrial cancer with the aim of evaluating the effectiveness of current follow-up procedures in terms of patient survival, as well as the convenience of modifying the surveillance strategy. Methods Retrospective descriptive study including all patients diagnosed with endometrial cancer relapse at the Department of Gynecology and Obstetrics of the Complejo Hospitalario Insular-Materno Infantil de Canarias, between 2005 and 2014. Results Recurrence was observed in 81 patients (10.04% of the sample); 66.7% of them suffered relapse within 2 years and 80.2% within 3 years after the termination of the primary treatment; 41.9% showed distant metastases while the rest corresponded to local-regional (40.7%) or ganglionar (17.4%) relapse; 42% of these were symptomatic; 14 patients showed more than 1 site of relapse. Relapse was detected mainly through symptoms and physical examination findings (54.3%), followed by elevated serummarker levels (29.6%), computed tomography (CT) images (9.9%) and abnormal vaginal cytology findings (6.2%). No differences in global survival were found between patients with symptomatic or asymptomatic relapse. Conclusion Taking into account that the recurrence rate of endometrial cancer is low, that relapse occurs mainly within the first 3 years post-treatment and that symptom evaluation and physical examination are the most effective follow-up methods, we postulate that a modification of the current model of hospital follow-up should be considered.